drugset / Trial / NCT05313802
A Study of LY3502970 in Healthy Overweight and Obese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Timeline
- Start
- 2022-05-26
- Primary completion
- 2022-09-09
- Completion
- 2022-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 3 mg | Oral |